Please assess the completion status of the following clinical trial:

Trial Title: Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 18-70 years~2. Patients with diagnosis of diffuse large B-cell lymphoma~3. Patients at high risk of CNS involvement (\>2 extranodal sites plus an elevated LDH or /and involvement of high-risk extranodal sites including testes, paranasal sinuses, breast, liver, adrenal and renal)~4. Patients who will receive HDMTX (three cycles) into R-CHOP regimen (6 cycles) prescribed according to normal clinical practice~5. Absence of focal neurological signs~6. Absence of CNS involvement determined by cerebrospinal fluid (CSF) cytometry flow test prior to start treatment~7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~8. Absolute neutrophil count 1800-7500/µL, platelet count 130.000- 450.000/ µL, hemoglobin 13,5-18 g/dL,~9. Serum creatinine ≤1.5 x the upper limit of normal (ULN) or glomerular filtration rate (GFR) ≥60ml/min/1.73m\^2~10. Total serum bilirubin ≤2 x ULN. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5 x ULN~11. Ability to understand and the willingness to sign a written informed consent document~12. In women of childbearing potential (from menarche and until becoming post-menopausal \[i.e., no menses for 12 months with an alternative medical cause\], unless permanently sterile) and men, use of highly effective measure of contraception (abstinence, hormonal contraception, intra-uterine device \[IUD\], intrauterine hormone-releasing system, \[IUS\], or anatomical sterility in self or partner) committed during 3 months after the last IMP administration.~Exclusion Criteria:~1. Malignant disease, other than those being treated in this study. Exceptions to this exclusion include malignancies that were treated curatively and have not recurred within 2 years after completion of treatment.~2. Patients suffered from cardiovascular diseases (arrhythmias, previous heart failure, thromboembolic disease)~3. Previous treatment with Glucarpidase~4. Pregnant or breastfeeding women~5. Concomitant treatment with agents which interact with methotrexate metabolism or excretion~6. Known intolerance/hypersensitivity to Glucarpidase or any of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Glucarpidase, methotrexate, R-CHOP (Type: EXPERIMENTAL): Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).